Relmada Therapeutics Announces 12-month Interim Data From Its Ongoing Phase 2 Trial Of NDV-01 For High-risk Non-muscle Invasive Bladder Cancer
Benzinga Newsdesk 7 months ago
BiotechHealth CareGeneral
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any timeTolerability profile remains
- Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC
- BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time
- Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations
- Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026